Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia.

ABSTRACT:

Background

Episodic angioedema with eosinophilia (EAE) is a rare multilineage cyclic syndrome of unknown etiology characterized by episodes of angioedema, myalgia, fatigue, and fever that occur every 3 to 8 weeks and resolve between episodes without therapy. Cyclic elevations in serum IL-5 levels and neutrophils precede the increase in absolute eosinophil count (AEC) in most patients.

Objective

We sought to assess the role of IL-5-driven eosinophilia in the clinical manifestations of EAE.

Methods

An open-label pilot study of mepolizumab (700 mg intravenously monthly for 3 months followed by sequential dose reduction to the Food and Drug Administration-approved dose of 300 mg subcutaneously monthly) was conducted. The primary end point was reduction in the number and s

SUBMITTER: Khoury P 

PROVIDER: S-EPMC10939939 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature